Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, gives her opinion on the key bladder cancer data from this meeting. Specifically, she focuses on nintedanib showing improved progression-free survival and overall survival in a subset of patients. This interview was recorded at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.